Limits...
Raltegravir in combination with other antiretroviral agents for the treatment of HIV infection.

Chirch LM, Steigbigel RT - Infect Drug Resist (2010)

Bottom Line: Raltegravir, an inhibitor of the HIV-1 integrase enzyme, is the first available agent in a new class of antiretroviral drugs.Raltegravir has been studied extensively in clinical trials, and has been well tolerated and highly effective in both treatment-naïve and -experienced patients.Resistance to raltegravir is unusual given its recent availability, but resistance with identified viral mutation pathways in the integrase gene in patients receiving the drug does occur.

View Article: PubMed Central - PubMed

Affiliation: Division of Infectious Diseases, Department of Medicine, Stony Brook University Medical Center, Stony Brook, New York, USA.

ABSTRACT
Raltegravir, an inhibitor of the HIV-1 integrase enzyme, is the first available agent in a new class of antiretroviral drugs. Raltegravir has been studied extensively in clinical trials, and has been well tolerated and highly effective in both treatment-naïve and -experienced patients. Resistance to raltegravir is unusual given its recent availability, but resistance with identified viral mutation pathways in the integrase gene in patients receiving the drug does occur.

No MeSH data available.


Related in: MedlinePlus

Percentage of patients (95% CI) achieving HIV RNA < 50 copies/mL.Copyright © Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Whitehouse Station, NJ, USA. All Rights Reserved.*P-value derived from a logistic regression model adjusted for baseline HIV RNA level (log10), first enfuvirtide use in optimized background therapy (OBT), first darunavir use in OBT, active protease inhibitors in OBT.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC3108745&req=5

f1-idr-3-015: Percentage of patients (95% CI) achieving HIV RNA < 50 copies/mL.Copyright © Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Whitehouse Station, NJ, USA. All Rights Reserved.*P-value derived from a logistic regression model adjusted for baseline HIV RNA level (log10), first enfuvirtide use in optimized background therapy (OBT), first darunavir use in OBT, active protease inhibitors in OBT.

Mentions: Although the BENCHMRK patient population represents a highly treatment-experienced group with multi-drug resistant virus, 96-week data reveal sustained and potent viral load reduction and CD4 count reconstitution in patients on raltegravir plus OBT, in comparison with placebo (Figures 1 and 2). Fifty-seven percent of patients on raltegravir had HIV-1 RNA levels of <50 copies/mL at 96 weeks, compared to 26% on placebo (P < 0.001, adjusted for baseline viral load, and first use of enfuvirtide, darunavir, or active PI in OBT). Change from baseline CD4 cell count was also significantly greater in patients receiving raltegravir plus OBT compared to placebo (123 vs 49 cells/mm3, respectively, P < 0.001).22


Raltegravir in combination with other antiretroviral agents for the treatment of HIV infection.

Chirch LM, Steigbigel RT - Infect Drug Resist (2010)

Percentage of patients (95% CI) achieving HIV RNA < 50 copies/mL.Copyright © Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Whitehouse Station, NJ, USA. All Rights Reserved.*P-value derived from a logistic regression model adjusted for baseline HIV RNA level (log10), first enfuvirtide use in optimized background therapy (OBT), first darunavir use in OBT, active protease inhibitors in OBT.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC3108745&req=5

f1-idr-3-015: Percentage of patients (95% CI) achieving HIV RNA < 50 copies/mL.Copyright © Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Whitehouse Station, NJ, USA. All Rights Reserved.*P-value derived from a logistic regression model adjusted for baseline HIV RNA level (log10), first enfuvirtide use in optimized background therapy (OBT), first darunavir use in OBT, active protease inhibitors in OBT.
Mentions: Although the BENCHMRK patient population represents a highly treatment-experienced group with multi-drug resistant virus, 96-week data reveal sustained and potent viral load reduction and CD4 count reconstitution in patients on raltegravir plus OBT, in comparison with placebo (Figures 1 and 2). Fifty-seven percent of patients on raltegravir had HIV-1 RNA levels of <50 copies/mL at 96 weeks, compared to 26% on placebo (P < 0.001, adjusted for baseline viral load, and first use of enfuvirtide, darunavir, or active PI in OBT). Change from baseline CD4 cell count was also significantly greater in patients receiving raltegravir plus OBT compared to placebo (123 vs 49 cells/mm3, respectively, P < 0.001).22

Bottom Line: Raltegravir, an inhibitor of the HIV-1 integrase enzyme, is the first available agent in a new class of antiretroviral drugs.Raltegravir has been studied extensively in clinical trials, and has been well tolerated and highly effective in both treatment-naïve and -experienced patients.Resistance to raltegravir is unusual given its recent availability, but resistance with identified viral mutation pathways in the integrase gene in patients receiving the drug does occur.

View Article: PubMed Central - PubMed

Affiliation: Division of Infectious Diseases, Department of Medicine, Stony Brook University Medical Center, Stony Brook, New York, USA.

ABSTRACT
Raltegravir, an inhibitor of the HIV-1 integrase enzyme, is the first available agent in a new class of antiretroviral drugs. Raltegravir has been studied extensively in clinical trials, and has been well tolerated and highly effective in both treatment-naïve and -experienced patients. Resistance to raltegravir is unusual given its recent availability, but resistance with identified viral mutation pathways in the integrase gene in patients receiving the drug does occur.

No MeSH data available.


Related in: MedlinePlus